drugset / Trial / NCT01973335

Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure

NCT01973335

RandomizedFactorialTriple-blindTreatment

Summary

This study has two primary objectives: 1. To compare combination therapy with acetazolamide and low-dose loop diuretics versus high-dose loop diuretics (standard of care) in patients with acute decompensated heart failure at high risk for diuretic resistance. 2. To demonstrate the safety and efficacy of upfront therapy with spironolactone in addition to loop diuretic therapy in patients with acute decompensated heart failure at high risk for diuretic resistance.

Timeline

Start
2013-11
Primary completion
2017-04
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetazolamide Small molecule 250 mg Intravenous
Subject Bumetanide Small molecule 1 mg Intravenous
Subject Spironolactone Small molecule 25 mg Oral

Indications